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This study explored if a combined supplementation of GH and IGF-1 had an additive eﬀect on whole body nitrogen economy,
energy, substrate and skeletal muscle metabolism following surgical trauma. Patients were randomized to controls (C; n = 10), to
GH (0.15IU/kg/injection) (GH; n = 7) or GH combined with IGF-1 (40μg/kg/injection) subcutaneously twice a day (GH-IGF-1;
n = 9) together with standardized parenteral nutrition. Muscle amino acids, glutathione and the ribosomal pattern reﬂecting
protein synthesis, and nitrogen balance were measured. GH- and GH-IGF-1 groups showed lower urea and higher plasma
glucose concentrations. Energy expenditure increased in the GH-group. GH-IGF-1 prevented a decrease in muscle polyribosomes
indicating a preserved muscle protein synthesis. In the GH group unaltered BCAA and AAA levels were seen in muscle indicating
an unchanged protein breakdown, while the other groups showed increased muscle concentrations postoperatively. Without
statistically diﬀerence GH marginally improved the nitrogen balance, in terms of higher values, and growth factors improved
the nitrogen balance when the shift in urea was taken into account. To conclude, growth factors inﬂuences urea metabolism,
protein degradation and protein synthesis. There was no clearcut additional eﬀect when combining GH and IGF-1 but the study
was probably underpowered to outrule this and eﬀects on nitrogen balance.
1.Introduction
Loss of lean body mass, and muscle tissue in particular,
may in critically ill patients be detrimental, and it increases
complications and impairs the clinical outcome. Therefore,
nutritional therapies together with therapies reducing the
catabolicburdenandimprovingleanbodymassareclinically
important [1]. Growth hormone has major eﬀects on
metabolism and aﬀects the utilization of substrates and
changes the tissue speciﬁc metabolism [2]. Several earlier
studies have shown its potential beneﬁts with regard to
protein metabolism, which also is reﬂected in clinically
positive eﬀects following surgery and in burn injuries [3–
9]. However, a large multicenter study involving critically ill
patients revealed an increased mortality in the GH-treated
group indicating that its eﬀects in situations with uncon-
trolled ongoing inﬂammation are associated with major
negative consequences [10]. The present study was planned
andcompletedbeforetheresultfromthemultinationalstudy
was reported.
Parts of the action of growth hormone are mediated
through the insulin-like growth factor-1 (IGF-1). Adminis-
trationofgrowthhormoneinducesariseincirculatingIGF-1
[11] that has important metabolic eﬀects in stimulating
glucose and amino acid uptake in muscle and improving
muscle protein synthesis [12, 13]. In catabolic situations
the levels of IGF-1 decrease while its binding proteins
increases leading to a lower local IGF-1 activity, contributing
to the decreased insulin sensitivity seen in catabolism
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The metabolic eﬀects of GH are at least in part mediated
through the action of IGF-1 produced in the liver and in the
peripheral tissues by the inﬂuence of growth hormone [17–
19]. In skeletal muscle a reduced gene-expression of the GH-
receptor is seen following surgical trauma [20]. This reduces
the local IGF-1 synthesis, an eﬀect that may be counteracted
by GH supplementation [21]. The interrelation between
GH, IGF-1 and IGF-binding proteins (GH/IGF-1/IGFBP-
a x i s )i st h u sa ﬀected mirrored by a lower GH sensitivity,
leading to lower IGF-1 and higher IGFBP levels that have
been described in ICU patients leading to a lower IGF-1
bioavailability [14, 22]. In septic patients decreased produc-
tion of IGF-1 has also been described [23] .T h ec h a n g ei n
theGH/IGF-1/IGFBP-axisispossibletocounteractbyamino
acid supplementation [24]. A similar eﬀect on the GH/IGF-
1/IGFBP-axis is seen in cardiac surgery when a glucose-
insulin-potassium (GIK) infusion is given peroperatively
[25]. IGF-1 levels have also been shown to be possible to
increase in catabolic patients, either by GH administration
or by giving IGF-1 [11, 26].
A combination of growth hormone and IGF-1 has a
theoretical beneﬁcial potential since the decreased insulin
sensitivity induced by growth hormone may be outbalanced
byanadditionofIGF-1.GHincreasesthebindingproteinfor
IGF and concomitant administration may therefore increase
the bioavailability of IGF-1 and increase its eﬀects on the
peripheral tissues. Combination of growth hormone and
IGF-1 with glutamine containing TPN has been shown to
improve protein balance in critically ill patients [27, 28], but
the combined eﬀect on nitrogen, amino acid, and protein
metabolism has so far not been explored following surgical
trauma. This study was designed to elucidate the eﬀects on
muscle amino acid, glutathione, and protein metabolism
of growth hormone alone or in combination with IGF-1
given together with continuous nutritional supplementation
following colonic resection as a human model of trauma.
The present study was discontinued when the report
of an increased mortality of ICU patients given GH was
published [10], but since the results may be of general
interest we hereby communicate this almost 10 years later.
2. Patientsand Methods
As a model of elective trauma metabolically healthy indi-
viduals under the age of 80, undergoing elective colonic
resection because of nonspread colonic cancer or earlier
diverticulitis, were included in this randomized and blinded
study (n = 26). Colonic resection was chosen as a surgical
trauma model leading to muscle catabolism, used in earlier
studies on muscle and nitrogen metabolism [29, 30]. The
operation is standardized, and metabolic changes indicating
a catabolic situation are seen during the early postoperatve
period [29, 30]. The characteristics of the patients and of the
operative procedures are shown in Table 1. They were pre-
operatively weight stable, not under medication aﬀecting the
metabolism, and none of them had signs of ongoing inﬂam-
mation. The patients were postoperatively given isocaloric
(28kcal/kg/24h) and isonitrogenous (0.15gN/kg/24h) TPN
(total parenteral nutrition), not containing glutamine, for
3days as a continuous infusion. One group served as a
control group (n = 10), another group was given GH
postoperatively (GH; n = 7) twice a day subcutaneously
(0.15IU/kg body weight/injection) and a third group (GH-
IGF-1; n = 9) was given the same amount of GH and IGF-1
(40μg/kg body weight/injection) twice a day. This dosages
has in earlier studies been shown to inﬂuence protein and
substrate metabolism [5, 11, 31–35]. The study was designed
to include 10 patients in each group, but when the use of
growth hormone in catabolic patients was stopped by the
results from the multicenter study on ICU patients [10]
inclusion of patients in the present study was stopped.
Preoperatively, after induction of anaesthesia, a muscle
biopsy was taken with percutaneous technique from the
vastus lateralis femoris muscle. The muscle tissue of about
200mg wet weight was divided into portions for the analyses
of the amino acid and glutathione concentration and the
content and size distribution of ribosomes, reﬂecting protein
synthesis. All visible fat and connective tissue were removed
from the tissue sample and the muscle tissue was weighed on
an electrobalance and then plunged into liquid nitrogen and
thereafter stored at −80◦C, until analysis. A second biopsy
was taken on the third postoperative day in local anaesthesia
conﬁned to the skin and fascia only. Daily blood samples
were taken for determination of the concentrations of amino
acids. Urine was collected in 24 hour portions for the
determination of the cumulated nitrogen losses. The study
protocolhasbeenapprovedbytheSwedishMedicalProducts
Agency (L¨ akemedelsverket) and by the Ethical Committee
of the Karolinska Institute, Stockholm, Sweden. The patients
were informed about the study procedure and of the possible
risks involved before consent was obtained.
2.1. Indirect Calorimetry. Energy expenditure and the res-
piratory quotient were measured by indirect calorimetry
preoperatively and on the second postoperative day (Delta-
trac, Datex Oi, Helsinki, Finland). The ﬁrst measurement
was made after an overnight fast before premedication. The
second measurement was made during continuous TPN
treatmentonthesecondpostoperativeday.Thepatientswere
measuredduringa30-minutelongperiodafter30minutesof
bedrest. Although the substrate availability may be diﬀerent
comparing these two situations the patients were measured
in a standardized way that allows comparisons between the
three groups.
2.2. Glucose, Urea, and CRP. Daily samples for determina-
tion of glucose, urea, and CRP were taken. Glucose was
determined by an enzymatic colorimetric method, urea by
a kinetic absorbance method and CRP by a quantitative
immunological method. All analyses were performed using
routine analyses at the hospital.
2.3. Nitrogen Balance. The whole-body nitrogen balance was
determined by subtracting the measured nitrogen excretion
in urine every 24-hour from the amino acid nitrogen content
in the TPN. The extrarenal losses were approximated to be
1.5g/24 hours that was included in the calculations.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
Table 1: Characteristics of the patients.
Control GH GH-IGF
Age (years) 72 (70–74) 70 (47–76) 69 (66–73)
Gender male/female 4/6 4/3 5/4
BMI 23.4 (20.9–25.1) 24.7 (22.7–28.8) 26.4 (22.4–28.1)
Op time (min) 90 (80–105) 95 (65–120) 90 (75–100)
Bleeding (mL) 175 (150–300) 200 (150–500) 280 (200–300)
Days of hospital stay 6.5 (5.0–7.0) 5.0 (4.0–6.0) 7 (6-7)
The urine was acidiﬁed and refrigerated immediately
after voiding. After collecting the 24-hour portions the vol-
ume was measured and aliquots were stored at −20◦Cp r i o r
to analysis of the daily losses of urea (Urease Enzymatic’s
UV test, Boeringer, Mannheim, Germany) ammonia (GLD,
kinetic UV test Merk, Darmstadt, Germany), and creatinine
(Jaﬀ´ e reaction, Beckman ASTRA, Palo Alto, USA). The total
nitrogen excretion was determined using chemolumines-
cence (771 C Pyroreactor, 720 C Nitrogen Detector; ANTEK,
Houston, Texas, USA).
Since treatment of growth factors signiﬁcantly decreased
the urea levels postoperatively, the contribution of the whole
body urea shift was also taken into account expressing a
urea related cumulated nitrogen balance [36]. Changes both
in total body water and urea were taken into account in
calculating the Urea-related nitrogen balance. In order to
assess total body water Body Impedance Analysis (BIA) was
used. The Urea related Nitrogen balance was calculated as
follows:
(i) Urea related N balance = N intake − N urine −
N extrarenal (approximated to be 1.5gN/24h) −
Diﬀ urea.
(ii) Diﬀurea =(ureaend − ureastart) ×total body water
(start)×0.028+(bodywaterend–bodywater(start))
× urea end × 0.028. (urea is expressed as mmol/L).
(iii) Extrarenal nitrogenlosses (N extrarenal) are esti-
mated to be 1.5 grams per day.
2.4. Amino Acids. Muscle tissue with a weight between 20–
40mg was used for analysis. The frozen muscle biopsy
specimenwashomogenizedin4%sulphosalicylicacid(SSA),
containing norleucine as internal standard. The procedure
is described in details elsewhere [37]. The amino acids were
separated on an Ultropae 8 Lithium form ion exchange resin
(Biochrom) using lithium citrate buﬀers. The amino acids
were detected and quantiﬁed by postcolumn derivatization
with o-phthaldialdehyde (OPA) and ﬂuorescent detection at
ex350nmem420nm.Theconcentrationsoftheaminoacids
were expressed as mmol/kg wet weight in muscle.
2.5. Glutathione and Thiols. Muscle tissue with a weight
between 20 and 40mg was used for analysis. Sample
preparation and derivatization have been described in details
elsewhere [38] .T h ef r o z e nm u s c l et i s s u ew a sh o m o g e n i z e d
and deproteinized in 6.5% sulphosalicylic acid (SSA) in a
glass homogenizer on ice. The homogenate was centrifuged
at 3.000×gf o r1 5m i n u t e sa t4 ◦C. The protein precipitate
was later used for the determination of protein-bound
GSH and CySH. Samples of GSH and CySH standards or
SSA-soluble fraction from muscle biopsies (100μL)w e r e
mixed with monobrombimane (mBBr) (8μMi ns o d i u m
N-ethylmorpholine pH 8.0, 100μL), allowed to react for
5minutes in the dark. Thereafterthe reaction wasstopped by
the addition of 100% SSA (10μL). Total glutathione (GSH
+ GSSG), total cysteine and precipitated protein were also
evaluated by the present method by performing a reduction
step of GSSG and CySS with dithiothreitol (DTT) after
protein precipitation.
The HPLC separation of thiol-bimane adducts was
achieved on a column (150 × 4.5mm) packed with 3μm
octadodecylsilica reversed-phase resin, followed by ﬂuores-
cent detection at ex 394nm, em 480nm.
2.6. Protein Synthesis. The protein synthesis in skeletal
muscle tissue was studied by the ribosome method [39].
Muscle tissue specimens of 50–60mg wet weight were used.
The samples were homogenized in a medium containing a
ribonuclease inhibitor and then centrifuged for 10minutes
at 1.500g. The pellet was saved for DNA determination by a
ﬂuorescence method. The supernatant was ultracentrifuged
for 2 hours at 102.000g. The pellet containing the ribosomal
particles was resuspended in 200μL of a medium contain-
ing a ribonuclease inhibitor. The ribosome concentration
was determined spectrophotometrically at 260nm and was
expressed as optical density (OD) units per milligram of
DNA. The remainder of the ribosomal suspension, 150μL,
was layered onto a gradient of sucrose between 0.4M and
1.5M. The tubes were ultracentrifuged for 60minutes in
a swing-out rotor. Afterwards the gradient was displaced
through a continuous-ﬂow cuvette and the absorbance at
260nm was recorded to show the distribution of ribosomes
and polyribosomes in the sucrose density gradient. The
area under the curve was measured and the percentage of
polyribosomes in the total ribosome area was calculated.
2.7. Statistical Analysis. The values are expressed as medians
with lower and upper quartiles. A nonparametric ANOVA
(Kruskal-Wallis ANOVA) was used followed by Wilcoxon
test for post hoc comparisons within the groups and Mann-
Withney U-test for comparisons between the controls and
the groups given growth factors. A P-value less than .05 was
considered as signiﬁcant. Borderline signiﬁcance (P<. 10)
was also indicated and discussed.4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
This was a pilot study in which the eﬀects on the primary
eﬀect variables were not known and therefore a power
analysis was not perforned. Since the variation coeﬃcient
was<5%fortheaminoacidanalyses,<10%fortheribosome
analyses, and <8% for the analyses of glutathione, groups
including 10 individuals each was considered suﬃcient to
detect a diﬀerence of a larger magnitude as the coeﬃcient of
variation in paired samples.
3. Results
3.1. Energy Expenditure and Glucose (Tables 2 and 3). The
energy expenditure increased postoperatively in the GH-
group by 15% (P = .024) but was unaltered in the other
groups. No statistically signiﬁcant changes were seen in
respiratory quotient within or between the groups, reﬂecting
that the relation between substrates used for oxidation was
not inﬂuenced by the surgical trauma or administration of
growth factors.
Plasma glucose concentrations increased postopera-
tively in all group. The controls were normalized on the
second postoperative day, while levels in the GH and
IGF-1/GH groups remained elevated throughout the study
period.
3.2. Urea and Nitrogen Balance (Tables 3 and 4). Plasma
urea decreased in both the GH- and GH-IGF-I groups on
the postoperative day 2 by 43% and 39% and on day 3 by
50% and 54% , respectively, compared to the control group
(P<. 05) in which no change was seen. The cumulated
postoperative nitrogen balance was positive in all groups
without any diﬀerences between the groups.
The urea corrected whole body cumulated nitrogen
balance (expressed as g N) was numerically more positive in
the GH group (11.43 (7.45–12.87)) compared to the control
group (6.84 (3.19–8.96)) and compared to the GH-IGF-1
group((8.92(5.82–18.27))butwithoutreachingasigniﬁcant
level, P = .063 and P = .22, respectively.
3.3. Amino Acids (Tables 5 and 6). Muscle glutamine
decreased in the control group by 28 %, by 24% in the
GH-group, and by 28% in the GH-IGF-1-group (P<. 05).
In parallel muscle BCAA increased by 44% in the control
group, by 39% (P<. 05) in the GH-IGF-1 group while no
changewasseenintheGH-group.Asimilarincreasewasalso
seen in the aromatic amino acids in muscle by 61% in the
control group and by 46% (P<. 05) in the GH-IGF-1 group.
No change was seen in the GH-group. Plasma glutamine
concentration decreased by 17% (P<. 05) in the GH-IGF-
1 group while the level was unchanged in the other groups.
3.4. Muscle Glutathione (Table 7). Total glutathione (tGSH)
and reduced glutathione (GSH) decreased in the GH group
by 16% and 12%, respectively, (P<. 05) and by 15% and
19%, respectively, in the GH-IGF-1 group (P<. 05). In the
controlsanumericaldecreaseby13%wasseenfortGSH,that
didnotattainstatisticalsigniﬁcance(P = .06)whileGSHwas
unaltered.
3.5. Ribosomes (Table 8). The concentrations of total ribo-
somes did not change in any of the groups postoperatively.
The polyribosome concentrations decreased by 19 % in
the control group and by 28 % in the GH group (P<. 05)
while the concentration was unchanged in the GH-IGF-1
group.
4. Discussion
In a human model of elective trauma the metabolic eﬀects
of GH either given alone or in combination with IGF-1,
together with total parenteral nutrition during three days
postoperatively were evaluated. Growth factors increased the
energy expenditure, increased the glucose and lowered the
urea levels. GH preserved the levels of BCAA and AAA
in skeletal muscle indicating that protein breakdown was
unaltered compared to increased postoperative levels in the
other groups. A combination of GH and IGF-1 preserved
the level of polyribosomes postoperatively indicating an
unaltered protein synthesis compared to decreases levels in
the other groups.
To combine growth hormone with either insulin or IGF-
1 may be advantageous since GH increases peripheral insulin
resistance and secondly since surgical trauma furthermore
increases GH resistance with lower levels of circulating IGF-
1. The eﬀect of IGF-1 given alone in catabolic conditions
is not as clear-cut as during growth hormone treatment. In
some studies IGF-1 given alone postoperatively showed no
eﬀect on nitrogen [26, 36]. IGF-1 treatment during 5 days
postoperatively reduced plasma insulin and glucose levels,
indicating an improved insulin sensitivity following surgery
[35].
In the present study a daily supply of GH (0.3IU/kg/day)
and IGF-1 (80μg/kg/day) was chosen since these amounts
have shown eﬀects on protein and substrate metabolism in
earlierstudiesduringthepostoperativeperiod[5,11,31–35].
Plasma glucose levels increased in both groups given
growth factors as compared to the control group. This
indicates an increased insulin resistance by growth factor
treatment. A tendency, although not statistically signiﬁcant,
towards higher levels in the GH-group compared to the GH-
IGF-1-group was observed.
As u ﬃcient energy and protein supply is a prerequisite
for an optimal IGF-I eﬀect and response to growth hormone
[40]. When compared to the resting energy consumption by
indirect calorimetry an excess of energy in the range between
400 to 600kcal per day was given in the present study every
day. This amount covers the energy consumption related to
the basal physical activity postoperatively. Treatment with
growth factors increased the resting energy expenditure
postoperatively compared to the control group without
changing the RQ.
This may be explained by the action of growth fac-
tors, increasing the metabolism of substrates. Both growth
hormone and IGF-I have in earlier studies been shown to
increase the resting energy metabolism following surgery
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Table 2: Respiratory quotient (RQ) and resting energy expenditure (REE) preoperatively and on the 2nd postoperative day. P < .10 are given
as numbers indicating changes within the groups. Values are given as medians and quartiles.
D0 D2
RQ Control 0.88 (0.85–0.96) 0.91 (0.87–0.95)
GH 0.89 (0.87–0.95) 0.87 (0.85–0.94)
GH-IGF-1 0.88 (0.84–0.90) 0.89 (0.79–0.94)
REE Control 1355 (1140–1450) 1380 (1270 –1650)
GH 1520 (1200–1650) 1750 (1610–1970) P = .024
GH-IGF-1 1470 (1240–1650) 1930 (1550–1970) P = .078
Table 3: Plasma glucose, urea and CRP levels pre- and postoperatively.
D0 D1 D2 D3
Glucose (mmol/L) Control 4.9 (4.3–5.4) 8.2 (6.2–9.8)∗ 6.6 (5.6–7.2) 5.8 (5.3–6.5)
GH 4.6 (3.9–5.2) 8.2 (6.8–11.1)∗ 8.2 (6.7–10.9)∗ 9.1 (7.0–11.2)∗#
GH-IGF-1 4.8 (4.7–5.2) 8.7 (7.3–8.9)∗∗ 7.4 (6.5–9.9)∗∗ 7.4 (6.9–12.6)∗∗#
Urea (mmol/L) Control 4.0 (3.1–5.2) 4.4 (3.1–5.3) 3.4 (3.1–3.5) 3.4 (3.2–4.1)
GH 4.0 (3.1–6.3) 3.1 (2.9–5.8) 2.3 (1.9–3.5)∗ 2.0 (1.4–2.9)∗#
GH-IGF-1 4.1 (3.5–4.9) 4.4 (3.5–4.9) 2.5 (2.0–2.9)∗ 1.9 (1.4–2.2)∗∗#
CRP (mg/L) Control 7 (5–13) 59 (55–91)∗∗ 104 (94–130)∗∗ 67 (59–109)∗∗
GH 5 (5–14) 46 (39–102)∗ 106 (43–145)∗ 69 (29–88)∗
GH-IGF-1 12 (5–20) 82 (66–86)∗∗ 135 (82–155)∗∗ 91 (53–114)∗∗
∗and ∗∗indicate a postoperative diﬀerence within the groups (P<. 05 and P<. 01) as compared to D0, and # indicates a diﬀerence between the controls and
the groups given growth factors (P<. 05). Values are given as medians and quartiles.
mitochondrial studies been shown to aﬀect mitochondrial
metabolism and substrate and energy metabolism and
increase the action of the uncoupling proteins [44]. This
may also be a contributing factor to the increased energy
metabolism seen in the groups given growth factors.
Urea levels decreased during the study period in both
the GH- and GH-IGF-1 groups mirroring a lower urea-
formation, an indirect sign of a decreased protein break-
down. Since the shift in whole body urea was signiﬁcant
in the GH- and GH-IGF-1 groups this was taken into
account in a calculation determining the cumulated nitrogen
balance related to the shift in urea. A tendency of an
improved whole body nitrogen balance during the study
period was seen in the groups given growth factors, the
eﬀect being close to signiﬁcant in the GH-group. In all
groups a positive nitrogen balance was seen which may be
explained by continuous administered parenteral nutrition.
This eﬀect on nitrogen balance has earlier been reported
when parenteral nutrition is administered continuously
[45].
In all three groups a similar decline in muscle glutamine
was seen postoperatively. This decline in glutamine was
not that extensive as has been shown in control groups
in earlier glutamine studies receiving a similar amino acid
composition as in the present study [30, 46]. There is no
clear explanation to this, but it is plausible that the contin-
uous administration of parenteral nutrition optimizes the
metabolic conditions to an extent that reduces the changes in
catabolic parameters. In the present study conventional TPN
was given without glutamine since that was not a clinical
routine at the time of the study.
A decline in muscle free glutamine has earlier been
reported to be reduced by GH-treatment [5] but this
ﬁnding was not reproduced. Changes in the total sum of
BCAA, aromatic and essential amino acid concentrations
diﬀered between the groups. An increase in BCAA and
AAA indicating an increased proteolysis was observed in the
control group and in the group given GH together with IGF-
1. The sum of essential amino acids in muscle increased
in the control group. These changes indicate that protein
degradation was reduced by GH treatment but not by the
combined therapy.
The total amount of glutathione and its reduced form
decreased postoperatively in all groups with the exception
of maintained levels of reduced glutathione in the control
group. No statistical diﬀerences were observed between the
groups. This observation is in line with results from earlier
studies in which muscle glutathione levels are aﬀected by
surgical trauma [30].
Muscle protein synthesis was assessed by determination
of the total amount and size distribution of ribosomes in
muscle tissue. The concentration of polyribosomes reﬂects
the protein synthesis activity in the tissue studied [32, 47].
The polyribosome concentrations decreased in the control
and GH-group but were statistically unchanged in the GH-
IGF-1 group. However using a nonparametric ANOVA no
diﬀerences were seen between the three groups, making this
observation not statistically robust enough.6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 4: Nitrogen balance during the postoperative period (g N). P <.10 are given as numbers indicating diﬀerences between the groups.
Values are given as medians and quartiles.
Control GH GH-IGF-1
N-balance day 1 2.84 (1.03–3.82) 4.14 (2.89–5.08) 3.04 (1.79–4.52)
N-balance day 2 0.44 (−0.80–1.84) 0.87 (-2.68–2.00) 1.25 (0.27–1.83)
N-balance day 3 2.04 (0.83–3.63) 3.43 (2.45–4.89) 3.09 (1.88–7.34)
Cumulated N-balance 6.28 (−0.01–8.26) 8.22 (5.34–9.74) 7.41 (3.39–14.11)
Cumulated N-bal urea 6.84 (3.19–8.96) 11.43 (7.45–12.87) P = .063 8.92 (5.82–18.27)
Table 5:Muscleaminoacids(mmol/kgwwmuscle).Glutamine(Gln),branchedchainaminoacids(BCAAs),aromaticaminoacids(AAAs),
essential amino acids (EAAs), total sum of amio acids (Tot AAs).
D0 D3
Gln Control 11.63 (10.46–12.87) 8.43 (8.14–9.07)∗∗
GH 11.49 (10.27–13.07) 8.75 (6.85–11.07)∗
GH-IGF-1 12.03 (10.72–12.93) 8.64 (10.99–6.57)∗∗
BCAA Control 0.38 (0.33–0.43) 0.55 (0.54–0.59)∗∗
GH 0.47 (0.38–0.51) 0.51 (0.44–0.55) #
GH-IGF-1 0.36 (0.35–0.39) 0.50 (0.48–0.60)∗∗
AAA Control 0.13 (0.97–1.47) 0.21 (0.19–0.23)∗∗
GH 0.15 (0.13–0.16) 0.17 (0.16–0.20)
GH-IGF-1 0.13 (0.10–0.15) 0.19 (0.17–0.20)∗
EAA Control 2.18 (2.07–2.43) 2.84 (2.53–3.12)∗∗
GH 2.16 (1.87–2.24) 2.26 (2.03–2.68) #
GH-IGF-1 2.11 (1.85–2.57) 2.54 (2.28–2.72)
Tot AA Control 21.26 (19.81–24.06) 18.69 (17.58–20.12)
GH 21.60 (18.77–23.62) 19.69 (14.36–21.78)
GH-IGF-1 21.84 (19.48–23.00) 19.53 (16.27–20.68)
∗and ∗∗indicate a postoperative diﬀerence within the groups (P < .05 and P <.01) as compared to D0, and # indicates a diﬀerence between the controls and
the groups given growth factors (P <. 05). Values are given as median and quartiles.
Table 6: Plasma amino acids (μmol/L). Glutamine (Gln), branched chain amino acids (BCAAs), aromatic amino acids (AAAs), essential
amino acids (EAAs), total sum of amio acids (Tot AAs).
D0 D3
Gln Control 554 (491–640) 510 (454–530)
GH 565 (511–606) 554 (436–568)
GH-IGF-1 581 (519–593) 478 (421–485)∗
BCAA Control 384 (258–417) 430 (376–473)
GH 405 (359–422) 416 (323–436)
GH-IGF-1 367 (280–393) 409 (362–447)
AAA Control 102 (85–115) 146 (127–157)∗∗
GH 114 (90–122) 118 (109–133)#
GH-IGF-1 109 (84–134) 121 (116–132)
EAA Control 983 (694–1054) 1094 (1016–1157)
GH 1010 (873–1126) 930 (806–1057)
GH-IGF-1 932 (892–1061) 965 (912–1039)
Tot AA Control 2123 (1720–2381) 2100 (2029–2389)
GH 2160 (1990–2397) 2129 (1722–2406)
GH-IGF-1 2254 (1991–2338) 2011 (1907–2113)
∗and ∗∗indicate a postoperative diﬀerence within the groups (P<. 05 and P<. 01) as compared to D0, # and indicates a diﬀerence between the controls and
the groups given growth factors (P<. 05). Values are given as median and quartiles.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
Table 7: Glutathione concentrations and redox-status of glutathione in skeletal muscle (mmol(kg ww muscle)). Total glutathione (tGSH),
reduced glutathione (GSH), oxidized glutathione (GSSG), and the redox-status of glutathione (GSH/tGSH).
D0 D3
tGSH Control 2.02 (1.78–2.16) 1.75 (1.59–1.95) P = .06
GH 2.03 (1.97–2.43) 1.71 (1.36–1.88)∗
GH-IGF-1 1.91 (1.71–1.98) 1.62 (1.40–1.79) P = .051
GSH Control 1.67 (1.49–1.86) 1.52 (1.30–1.76)
GH 1.65 (1.52–2.16) 1.45 (1.02–1.74)∗
GH-IGF-1 1.65 (1.50–1.73) 1.33 (1.25–1.47)∗
GSSG Control 0.17 (0.13–0.18) 0.13 (0.11–0.16)
GH 0.18 (0.10–0.22) 0.15 (0.07–0.17)
GH-IGF-1 0.13 (0.10–0.15) 0.15 (0.09–0.18)
GSH/tGSH Control 0.83 (0.80–0.88) 0.86 (0.82–0.89)
GH 0.83 (0.77–0.90) 0.86 (0.75–0.91)
GH-IGF-1 0.85 (0.84–0.90) 0.83 (0.81–0.87)
∗indicates a postoperative diﬀerence within the groups (P<. 05 and P<. 01). P<. 10 are given as numbers. Values are given as median and quartiles.
Table 8: Ribosome and polyribosome concentrations (OD/mg DNA) in skeletal muscle.
D0 D3
Tot rib Control 39.4 (35.1–48.5) 35.4 (30.7–43.4)
GH 39.3 (33.2–46.7) 36.7 (30.8–38.8)
GH-IGF-1 38.0 (34.1–38.8) 36.8 (33.6–44.8)
Poly rib Control 18.7 (14.6–21.6) 15.1 (12.8–19.7)∗
GH 20.9 (19.8–21.6) 15.0 (11.6–17.1)∗
GH-IGF-1 16.8 (16.3–18.2) 15.7 (14.9–20.5)
∗indicates a postoperative diﬀerence within the groups (P<. 05) as compared to D0. Values are given as median and quartiles.
There are historically studies with clinical beneﬁcial
eﬀects with the use of GH [3, 6, 7, 9], but when used
in a heterogeneous group of ICU patients with ongoing
acute general inﬂammation an increased mortality is seen
[10]. The mechanism behind that adverse eﬀect may be
increased insulin resistance, uncontrolled hyperglycemia,
uncontrolled nutritional supply, a triggering of the inﬂam-
matory response, and a shortage of substrates for the
immune system induced by a decreased peripheral release of
glutamine.
It is important to consider a proper timing with regard
to the inﬂammatory response, and a proper glucose control
and to pay attention to the nutritional treatment. This has
been elucidated in a recent study presenting metabolically
positive eﬀects when GH was administered in a pulsative
way together with glutamine in ICU patients [48]. Despite
the negative eﬀect of GH treatment used in unselected ICU
patients earlier there may still be a future for GH- treatment
in selected ICU patients.
The present study showed eﬀects on muscle amino
acids indicating a lower protein degradation when GH was
used, an prevention of a drop in postoperative protein
synthesis when the combination of GH- and IGF-1 was
given. Growth factors have a clear eﬀect on plasma urea
indicating reduced gluconeogenesis. Even when the change
in urea was taken into consideration a signiﬁcant diﬀerence
was not seen between the control and groups given growth
factors. The patients were all in positive nitrogen balance, a
situation that was not further pronounced by treatment with
growth factors.
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